BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castrucci MR. Factors affecting immune responses to the influenza vaccine. Hum Vaccin Immunother 2018;14:637-46. [PMID: 28617077 DOI: 10.1080/21645515.2017.1338547] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Qiu P, Zhou Y, Wang F, Wang H, Zhang M, Pan X, Zhao Q, Liu J. Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. Aging Clin Exp Res 2020;32:1869-78. [PMID: 32734576 DOI: 10.1007/s40520-020-01664-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 25.5] [Reference Citation Analysis]
2 Esposito S. 100 years since the 1918 influenza pandemic. Hum Vaccin Immunother 2018;14:504-7. [PMID: 29553916 DOI: 10.1080/21645515.2018.1446591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Jecker NS, Wightman AG, Diekema DS. Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines. J Med Ethics 2021:medethics-2020-107036. [PMID: 33593876 DOI: 10.1136/medethics-2020-107036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection 2020;81:e16-25. [DOI: 10.1016/j.jinf.2020.04.021] [78495111110.1016/j.jinf.2020.04.021','', '1007-9327')">Reference Citation Analysis]
5 Verstraeten T, Fletcher MA, Suaya JA, Jackson S, Hall-Murray CK, Scott DA, Schmöle-Thoma B, Isturiz RE, Gessner BD. Diabetes mellitus as a vaccine-effect modifier: a review. Expert Rev Vaccines 2020;19:445-53. [PMID: 32516066 DOI: 10.1080/14760584.2020.1760098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Fragkou PC, Moschopoulos CD, Reiter R, Berger T, Skevaki C. Host immune responses and possible therapeutic targets for viral respiratory tract infections in susceptible populations: a narrative review. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.03.010] [Reference Citation Analysis]
7 Wen S, Wu Z, Zhong S, Li M, Shu Y. Factors influencing the immunogenicity of influenza vaccines. Hum Vaccin Immunother 2021;17:2706-18. [PMID: 33705263 DOI: 10.1080/21645515.2021.1875761] [Reference Citation Analysis]
8 Rogers LRK, de Los Campos G, Mias GI. Microarray Gene Expression Dataset Re-analysis Reveals Variability in Influenza Infection and Vaccination. Front Immunol 2019;10:2616. [PMID: 31787983 DOI: 10.3389/fimmu.2019.02616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81:e16-e25. [PMID: 32335169 DOI: 10.1016/j.jinf.2020.04.021] [Cited by in Crossref: 714] [Cited by in F6Publishing: 659] [Article Influence: 357.0] [Reference Citation Analysis]
10 Wang Y, Tang CY, Wan XF. Antigenic characterization of influenza and SARS-CoV-2 viruses. Anal Bioanal Chem 2021. [PMID: 34905077 DOI: 10.1007/s00216-021-03806-6] [Reference Citation Analysis]
11 Clarke M, Goodchild LM, Evans S, Giles LC, Sullivan SG, Barr IG, Lambert S, Marshall H. Body mass index and vaccine responses following influenza vaccination during pregnancy. Vaccine 2021;39:4864-70. [PMID: 34266699 DOI: 10.1016/j.vaccine.2021.06.065] [Reference Citation Analysis]
12 Sykes A, Gerhardt E, Tang L, Adderson EE. The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia. J Pediatr 2017;191:218-224.e1. [PMID: 29173310 DOI: 10.1016/j.jpeds.2017.08.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Dougas G, Mavrouli M, Vrioni G, Lytras T, Mellou K, Metallidis S, Istikoglou I, Mitrou K, Tzani M, Georgopoulou I, Tsalikoglou F, Garetsou E, Poulakou G, Giannitsioti E, Moschopoulos C, Baka A, Georgakopoulou T, Tsiodras S, Tsakris A. Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals. Vector Borne Zoonotic Dis 2020;20:303-9. [PMID: 31794689 DOI: 10.1089/vbz.2019.2526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Tian M, Yu J, Lillvis DF, Vexler A. Influence function methods to assess the effectiveness of influenza vaccine with survey data. Health Serv Res 2021. [PMID: 34643942 DOI: 10.1111/1475-6773.13895] [Reference Citation Analysis]
15 Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: Past, present, and future. Rev Med Virol 2021;:e2243. [PMID: 33949021 DOI: 10.1002/rmv.2243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Frasca D, Blomberg BB, Garcia D, Keilich SR, Haynes L. Age-related factors that affect B cell responses to vaccination in mice and humans. Immunol Rev 2020;296:142-54. [PMID: 32484934 DOI: 10.1111/imr.12864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
17 Kimball J, Zhu Y, Wyatt D, Trabue CH, Talbot HK. Influenza Vaccine Failure Associated With Age and Immunosuppression. J Infect Dis 2021;224:288-93. [PMID: 33340042 DOI: 10.1093/infdis/jiaa757] [Reference Citation Analysis]
18 Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications. Vaccines (Basel) 2021;9:862. [PMID: 34451987 DOI: 10.3390/vaccines9080862] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Djordjević ZM, Gavrilović J, Suša R, Pejčić AV, Popovska-jovičić B, Čanović P, Živković-zarić RS, Milosavljević MN, Opančina VD, Petrović IK, Čekerevac I, Lazić Z, Folić MM, Novković L, Janković SM. Factors Associated with Death of Covid-19 Patients: Case Series. Serbian Journal of Experimental and Clinical Research 2022;0. [DOI: 10.2478/sjecr-2021-0036] [Reference Citation Analysis]
20 Basu I, Agarwal M, Shah V, Shukla V, Naik S, Supe PD, Srivastava MK, Giriraja KV, Pinjar P, Mishra PK, Joshi S, Vijayakumar R, van de Witte S. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study. Hum Vaccin Immunother 2021;:1-10. [PMID: 33957854 DOI: 10.1080/21645515.2021.1885278] [Reference Citation Analysis]
21 Riese P, Guzmán CA. Roads to advanced vaccines: influenza case study. Microb Biotechnol 2017;10:1036-40. [PMID: 28809451 DOI: 10.1111/1751-7915.12835] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Zhong S, Wei H, Li M, Cheng Y, Wen S, Wang D, Shu Y. Single Nucleotide Polymorphisms in the Human Leukocyte Antigen Region Are Associated With Hemagglutination Inhibition Antibody Response to Influenza Vaccine. Front Genet 2022;13:790914. [DOI: 10.3389/fgene.2022.790914] [Reference Citation Analysis]
23 Amdam H, Madsen A, Zhou F, Bansal A, Trieu MC, Cox RJ. Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Front Immunol 2021;12:748281. [PMID: 34938285 DOI: 10.3389/fimmu.2021.748281] [Reference Citation Analysis]
24 Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing 2020;17:37. [PMID: 33292323 DOI: 10.1186/s12979-020-00210-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
25 Norman DA, Cheng AC, Macartney KK, Moore HC, Danchin M, Seale H, McRae J, Clark JE, Marshall HS, Buttery J, Francis JR, Crawford NW, Blyth CC. Influenza hospitalizations in Australian children 2010-2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness. Influenza Other Respir Viruses 2021. [PMID: 34787369 DOI: 10.1111/irv.12939] [Reference Citation Analysis]
26 Domnich A, Manini I, Calabrò GE, Waure C, Montomoli E. Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses. Vaccines (Basel) 2019;7:E215. [PMID: 31847273 DOI: 10.3390/vaccines7040215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB. B Cell Immunosenescence. Annu Rev Cell Dev Biol 2020;36:551-74. [PMID: 33021823 DOI: 10.1146/annurev-cellbio-011620-034148] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
28 Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J 2020;39:700-5. [PMID: 32516282 DOI: 10.1097/INF.0000000000002747] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
29 Agbarya A, Sarel I, Ziv-Baran T, Agranat S, Schwartz O, Shai A, Nordheimer S, Fenig S, Shechtman Y, Kozlener E, Taha T, Nasrallah H, Parikh R, Elkoshi N, Levy C, Khoury R, Brenner R. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers (Basel) 2021;13:4191. [PMID: 34439346 DOI: 10.3390/cancers13164191] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Hanson HA, Leiser CL, Bandoli G, Pollock BH, Karagas MR, Armstrong D, Dozier A, Weiskopf NG, Monaghan M, Davis AM, Eckstrom E, Weng C, Tobin JN, Kaskel F, Schleiss MR, Szilagyi P, Dykes C, Cooper D, Barkin SL. Charting the life course: Emerging opportunities to advance scientific approaches using life course research. J Clin Transl Sci 2020;5:e9. [PMID: 33948236 DOI: 10.1017/cts.2020.492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons. Clin Infect Dis 2021;73:816-23. [PMID: 33605977 DOI: 10.1093/cid/ciab152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
32 Bufan B, Arsenović-Ranin N, Petrović R, Živković I, Stoiljković V, Leposavić G. Strain specificities in influence of ageing on germinal centre reaction to inactivated influenza virus antigens in mice: Sex-based differences. Exp Gerontol 2020;133:110857. [PMID: 32006634 DOI: 10.1016/j.exger.2020.110857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, Vermeulen W, Verhoeven C, Leav B, Zhang B, Sawlwin D, Hamers-Heijnen E, Edelman J, Smolenov I. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis 2021;21:1027-37. [PMID: 33577767 DOI: 10.1016/S1473-3099(20)30694-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
34 Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season. Int J Environ Res Public Health 2019;16:E4489. [PMID: 31739554 DOI: 10.3390/ijerph16224489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Li D, Liu C, Liu J, Hu J, Yang Y, Zhou Y. Analysis of Risk Factors for 24 Patients With COVID-19 Developing From Moderate to Severe Condition. Front Cell Infect Microbiol 2020;10:548582. [PMID: 33042873 DOI: 10.3389/fcimb.2020.548582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Raboni SM, Moura FEA, Caetano BC, Avanzi VM, Pereira LA, Nogueira MB, Vidal LR, Tavares ICF, Pradel FK, Picot VS, Puig-Barbera J, Siqueira MM. Global Influenza Hospital-based Surveillance Network (GIHSN): results of surveillance of influenza and other respiratory viruses in hospitalised patients in Brazil, 2015. BMJ Open 2018;8:e017603. [PMID: 29449287 DOI: 10.1136/bmjopen-2017-017603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Yoon Y, Choi JS, Park M, Cho H, Park M, Huh HJ, Kim YJ, Son MH. Influenza Vaccine Effectiveness in Children at the Emergency Department during the 2018-2019 Season: the First Season School-aged Children Were Included in the Korean Influenza National Immunization Program. J Korean Med Sci 2021;36:e71. [PMID: 33724738 DOI: 10.3346/jkms.2021.36.e71] [Reference Citation Analysis]
38 Law N, Kumar D. Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. Drugs Aging 2017;34:743-54. [PMID: 28965331 DOI: 10.1007/s40266-017-0491-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Machado A, Leite A, Larrauri A, Gomez V, Rodrigues AP, Kislaya I, Nunes B. No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons. Pharmacoepidemiol Drug Saf 2021;30:1411-9. [PMID: 34096151 DOI: 10.1002/pds.5302] [Reference Citation Analysis]
40 Hodgins B, Pillet S, Landry N, Ward BJ. Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge. Immun Ageing 2019;16:27. [PMID: 31700523 DOI: 10.1186/s12979-019-0167-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
41 Anjorin AA, Adepoju BA. Serologic evidence of seasonal influenza A and B in HIV patients on combined antiretroviral therapy in Lagos, Nigeria. Afr J Lab Med 2020;9:1048. [PMID: 33392051 DOI: 10.4102/ajlm.v9i1.1048] [Reference Citation Analysis]
42 Hensen L, Nguyen THO, Rowntree LC, Damelang T, Koutsakos M, Aban M, Hurt A, Harland KL, Auladell M, van de Sandt CE, Everitt A, Blacker C, Oyong DA, Loughland JR, Webb JR, Wines BD, Hogarth PM, Flanagan KL, Plebanski M, Wheatley A, Chung AW, Kent SJ, Miller A, Clemens EB, Doherty PC, Nelson J, Davies J, Tong SYC, Kedzierska K. Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proc Natl Acad Sci U S A 2021;118:e2109388118. [PMID: 34607957 DOI: 10.1073/pnas.2109388118] [Reference Citation Analysis]